Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) and Adherex Technologies (NASDAQ:FENC – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.
Earnings & Valuation
This table compares Anebulo Pharmaceuticals and Adherex Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anebulo Pharmaceuticals | N/A | N/A | -$8.48 million | ($0.19) | -1.77 |
| Adherex Technologies | $44.64 million | 8.20 | -$9.74 million | ($0.29) | -36.17 |
Risk & Volatility
Anebulo Pharmaceuticals has a beta of -1.83, meaning that its share price is 283% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Anebulo Pharmaceuticals and Adherex Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anebulo Pharmaceuticals | 1 | 1 | 0 | 0 | 1.50 |
| Adherex Technologies | 1 | 1 | 4 | 1 | 2.71 |
Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 46.81%. Given Adherex Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Anebulo Pharmaceuticals.
Profitability
This table compares Anebulo Pharmaceuticals and Adherex Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anebulo Pharmaceuticals | N/A | -74.57% | -68.96% |
| Adherex Technologies | -17.12% | -43.87% | -11.35% |
Insider and Institutional Ownership
28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Adherex Technologies beats Anebulo Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Anebulo Pharmaceuticals
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
About Adherex Technologies
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
